

# MEDICINES RECALL

## CLASS 3 MEDICINES RECALL, EL(26)A/07

Action within 5 days

Issued 04 February 2026

Distribute to Pharmacy/Wholesaler Level

### MARKETING AUTHORISATION HOLDER (MAH)

Aspar Pharmaceuticals Ltd

### MEDICINE DETAILS

**Ibuprofen 200 mg Tablets**

**Ibucalm 200 mg Tablets**

PL: 08977/0016

Active Ingredient: ibuprofen

SNOMED code: N/A

GTIN: 5010441006481 (Numark), 5060057401989 (Almus), 5024071270358 (Ibucalm)

### AFFECTED LOT BATCH NUMBERS

Batch No.	Expiry Date	Pack Size	First Distributed
<b>250135 Almus</b>	31/12/2026	24	18/06/2025
<b>250399 Almus</b>	30/06/2027	24	04/08/2025
<b>250125 Numark</b>	31/12/2026	24	27/05/2025
<b>250109 Aspar</b>	31/12/2026	48	25/03/2025

### Background

Aspar Pharmaceuticals Ltd is recalling specific batches distributed in Aspar, Almus and Numark livery. The batches are being recalled as a precautionary measure following findings of foil perforations in some blisters. The investigation confirmed that other batches were not impacted since the issue is related to a specific batch of aluminium foil utilised for these four batches of tablets. These products are Pharmacy (P) medicines and can only be sold or

## MEDICINES NOTIFICATION

dispensed from a registered pharmacy premises by a pharmacist, or by staff acting under their direct supervision.

### **Advice for Healthcare Professionals:**

Stop supplying the above batches immediately. Quarantine all stock and return it to your supplier using your supplier's approved process.

### **Advice for Healthcare Professionals to Provide to Patients:**

No further action is required by patients as this recall is being undertaken at a Pharmacy and Wholesaler level as a precautionary measure. Patients should continue to take medicines from these batches as prescribed by your healthcare professional.

Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the [MHRA Yellow Card scheme](#).

### **Additional information:**

For all enquiries regarding this product, please call 020 8205 9846 extension 2209 or email [adrian.zahra@aspar.co.uk](mailto:adrian.zahra@aspar.co.uk).

Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Yours faithfully

**Defective Medicines Report Centre**  
**10 South Colonnade**  
**Canary Wharf**  
**London**  
**E14 4PU**

**Telephone +44 (0)20 3080 6574**

**[DMRC@mhra.gov.uk](mailto:DMRC@mhra.gov.uk)**